S-nitrosoglutathione preserves platelet function during in vitro ventricular assist device circulation

ASAIO Journal

Volumn 48, Issue 5, 2002, Pages 526-531

  Aledia, Anna S ^a   Tran, Lisa M ^a   King, Bryan O ^a   Serna, Dan L ^a   Eng, Jamie ^a   Jones, Blanding U ^a   Chen, John C ^a   Roum, James H ^a  

^a Bldg 53 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLOMERATION; BIOLOGICAL MATERIALS PRESERVATION; BLOOD; COLLAGEN; NITROGEN OXIDES; TITRATION;

PLATELET FUNCTIONS;

HEMODYNAMICS;

COLLAGEN; NITRIC OXIDE; RISTOCETIN; S NITROSOGLUTATHIONE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; HEART ASSIST DEVICE; HUMAN; IN VITRO STUDY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

EID: 0036738979     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002480-200209000-00015     Document Type: Article

References (41)

1. Di Bella I, Pagani F, Banfi C, et al: Results with the Novacor assist system and evaluation of long-term assistance. Eur J Cardiothorac Surg 18: 112-116, 2000.
2. Mohacsi P, Deng MC, Murphy R, etal: Implantable left ventricular assist systems (LVAS): Recent results. A report from a series of meetings sponsored by the Study Group on Advanced Heart Failure of the Working Group on Heart Failure. Eur J Heart Fail 2: 13-18, 2000.
3. Morales DL, Argenziano M, Oz MC: Outpatient left ventricular assist device support: A safe and economical therapeutic option for heart failure. Prog Cardiovasc Dis 43: 55-66, 2000.
4. Chen JC, Serna DL, Tran LM, et al: Protection of platelet glycoprotein IIb/IIIa receptor complex preserves platelet function during in vitro ventricular assisted circulation. ASAIO J 44: M682-M684, 1998.
5. Serna DL, King BO, Huh J, Jalal R, Tran L, Chen JC: Evidence for selective degradation of platelet GP IIb/IIIa complex after prolonged in vitro ventricular assist. J Investig Med 46: 279-283, 1998.
6. al-Mondhiry H, Pae WE, Miller CA, Pierce WS: Platelet and fibrinogen survival in calves implanted with artificial heart and ventricular assist device: Correlation with autopsy findings. Thromb Haemost 67: 413-416, 1992.
7. Himmelreich G, Ullmann H, Riess H, et al: Pathophysiologic role of contact activation in bleeding followed by thromboembolic complications after implantation of a ventricular assist device. ASAIO J 41: M790-M794, 1995.
8. Livingston ER, Fisher CA, Bibidakis EJ, et al: Increased activation of the coagulation and fibrinolytic systems leads to hemorrhagic complications during left ventricular assist implantation [see comments]. Circulation (Suppl 2) 94: 227-234, 1996.
9. Matsubayashi H, Fastenau DR, McIntyre JA: Changes in platelet activation associated with left ventricular assist system placement. J Heart Lung Transplant 19: 462-468, 2000.
10. Radomski M, Palmer RM, Moncada S: An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 87: 5193-5197, 1990.
11. Radomski MW, Palmer RM, Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2: 1057-1058, 1987.
12. Yomo T, Serna DL, Powell LL, et al: Glycoprotein IIb/IIIa receptor inhibitor attenuates platelet aggregation induced by thromboxane A2 during in vitro nonpulsatile ventricular assist circulation. Artif Organs 24: 355-361, 2000.
13. Radomski MW, Palmer RM, Read NG, Moncada S: Isolation and washing of human platelets with nitric oxide. Thromb Res (Suppl) 50: 537-546, 1988.
14. Wang GR, Zhu Y, Halushka PV, Lincoln TM, Mendelsohn ME: Mechanism of platelet inhibition by nitric oxide: In vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci U S A 95: 4888-4893, 1998.
15. Jilma B, Hergovich N, Stohlawetz P, et al: Effects of sodium nitroprusside on hemodialysis-induced platelet activation. Kidney Int 55: 686-691, 1999.
16. Stohlawetz P, Horvath M, Pernerstorfer T, et al: Effects of nitric oxide on platelet activation during plateletpheresis and in vivo tracking of biotinylated platelets in humans. Transfusion 39: 506-514, 1999.
17. Mellion BT, Ignarro LJ, Myers CB, et al: Inhibition of human platelet aggregation by s-nitrosothiols: Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol 23: 653-664, 1983.
18. Simon DI, Stamler JS, Jaraki O, et al: Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. Arterioscler Thromb 13: 791-799, 1993.
19. Stamler JS, Simon DI, Osborne JA, et al: S-nitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds. Proc Natl Acad Sci U S A 89: 444-448, 1992.
20. Stamler JS: S-nitrosothiols and the bioregulatory actions of nitrogen oxides through reactions with thiol groups [Review]. Curr Top Microbiol Immunol 196: 19-36, 1995.
21. Wink DA, Nims RW, Darbyshire JF, et al: Reaction kinetics for nitrosation of cysteine and glutathione in aerobic nitric oxide solutions at neutral pH: Insights into the fate and physiological effects of intermediates generated in the NO/O2 reaction. Chem Res Toxicol 7: 519-525, 1994.
22. Radomski MW, Rees DD, Dutra A, Moncada S: S-nitrosoglutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol 107: 745-749, 1992.
23. Salas E, Langford EJ, Marrinan MT, Martin JF, Moncada S, de Belder AJ: S-nitrosoglutathione inhibits platelet activation and deposition in coronary artery saphenous vein grafts in vitro and in vivo. Heart 80: 146-150, 1998.
24. de Belder AJ, MacAllister R, Radomski MW, Moncada S, Vallance PJT: Effects of S-nitroso-glutathione in the human forearm circulation: Evidence for selective inhibition of platelet activation. Cardiovasc Res 28: 691-694, 1994.
25. Langford EJ, Brown AS, Wainwright RJ, et al: Inhibition of platelet activity by s-nitrosoglutathione during coronary angioplasty. Lancet 344: 1458-1460, 1994.
26. Molloy J, Martin JF, Baskerville PA, Fraser SCA, Markus HS: S-nitrosoglutathione reduces the rate of embolizations in humans. Circulation 98: 1372-1375, 1998.
27. Moroi M, Jung SM: Platelet receptors for collagen. Thromb Haemost 78: 439-444, 1997.
28. Arita H, Nakano T, Hanasaki K: Thromboxane A2: Its generation and role in platelet activation [Review]. Prog Lipid Res 28: 273-301, 1989.
29. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJD: Clinical implications of prostaglandin and thromboxane A2 formation (2) [Review]. N Engl J Med 319: 761-767, 1988.
30. Askew SC, Butler AR, Flitney FW, Kemp GD, Megson IL: Chemical mechanisms underlying the vasodilator and platelet anti- aggregating properties of S-nitroso-N-acetyl-DL-penicillamine and S-nitrosoglutathione. Bioorg Med Chem 3: 1-9, 1995.
31. Gordge MP, Hothersall JS, Neild GH, Noronha-Dutra AA: Role of a copper (1)-dependent enzyme in the anti-platelet action of s-nitrosoglutathione. Br J Pharmacol 119: 533-538 1996.
32. Anfossi G, Russo I, Massucco P, et al: L-arginine modulates aggregation and intracellular cyclic 3′,5′-guanosine monophosphate levels in human platelets: direct effect and interplay with antioxidative thiol agent. Thromb Res 94: 307- 316, 1999.
33. Bode-Boger SM, Boger RH, Galland A, Frolich JC: Differential inhibition of human platelet aggregation and thromboxane A2 formation by L-arginine in vivo and in vitro. Naunyn-Schmiedebergs Arch Pharmacol 357: 143-150, 1998.
34. Gordge MP, Hothersall JS, Noronha-Dutra AA: Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione. Br J Pharmacol 124: 141-148, 1998.
35. Hayashi Y, Sawa Y, Nishimura M, et al: Nitric oxide gas infusion to the oxygenator enhances the biocompatibility of heparin coated extracorporeal bypass circuits. ASAIO J 44: M456-M461, 1998.
36. Fressinaud E, Meyer D: Von Willebrand factor and platelet inter-actions with the vessel wall. Blood Coagul Fibrinolysis 2: 333-340, 1991.
37. Hamet P, Coquil JF: Cyclic GMP binding and cyclic GMP phosphodiesterase in rat platelets. J Cyclic Nucleotide Res 4: 281-290, 1978.
38. Hashimoto E, Takeda M, Nishizuka Y, Hamana K, Iwai K: Studies on the sites in histones phosphorylated by adenosine 3′:5′-monophosphate-dependent and guanosine 3′:5′-monophosphate-dependent protein kinases. J Biol Chem 251: 6287-6293, 1976.
39. Haslam RJ, Salama SE, Fox JEB: Roles of cyclic nucleotides and of protein phosphorylation in regulation of platelet function, in Rotman A, Meyer FA, Gitler C, Silberberg A (eds), Platelets: Cellular Response Mechanisms and Their Biological Significance, Chichester, England: Wiley, 1980.
40. Takai Y, Kaibuchi K, Sano K, Nishizuka Y: Counteraction of calcium-activated, phospholipid-dependent protein kinase activation by adenosine 3′,5′-monophosphate and guanosine 3′, 5′-monophosphate in platelets. J Biochem (Tokyo) 91: 403-406, 1982.
41. Hoylaerts MF: Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor [Review]. Verh K Acad Geneeskd Belg 59: 161-183, 1997.